Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
81.59B
Market cap81.59B
Price-Earnings ratio
18.48
Price-Earnings ratio18.48
Dividend yield
0.46%
Dividend yield0.46%
Average volume
738.02K
Average volume738.02K
High today
$779.75
High today$779.75
Low today
$765.77
Low today$765.77
Open price
$774.25
Open price$774.25
Volume
453.27K
Volume453.27K
52 Week high
$792.77
52 Week high$792.77
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

Regeneron(REGN) stock is priced at $776.31, giving the company a market capitalization of 81.59B. It carries a P/E multiple of 18.48 and pays a dividend yield of 45.6%.

On 2026-01-03, Regeneron(REGN) stock moved within a range of $765.77 to $779.75. With shares now at $776.31, the stock is trading +1.4% above its intraday low and -0.4% below the session's peak.

Trading activity shows a volume of 453.27K, compared to an average daily volume of 738.02K.

The stock's 52-week range extends from a low of $476.49 to a high of $792.77.

The stock's 52-week range extends from a low of $476.49 to a high of $792.77.

REGN News

TipRanks 4d
Regeneron Advances Phase 3 Antibody Trial in Birch Pollen Eye Allergy: What Investors Should Know

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks This Holiday Season Unlock hedge fund-level data an...

Analyst ratings

67%

of 30 ratings
Buy
66.7%
Hold
30%
Sell
3.3%

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.